Topics

ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

06:50 EDT 11 Jul 2019 | Pharmaceutical Business Review

The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate (TAF)-containing

The post ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint appeared first on Pharmaceutical Business review.

Original Article: ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

NEXT ARTICLE

More From BioPortfolio on "ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint"

Quick Search

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...